American British Cowdray Medical Center Report issue

Foundation Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2013
NCT01868802
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

American British Cowdray Medical Center | Paul J. Lamothe | The American British Cowdray Medical Center. I.A.P.

Active Ingredients

Drugs in Phase 4 Trials (1)

ropivacaine (naropin) (1 trial)

Drugs in Phase 3 Trials (4)

acetylcysteine (mucomyst) (1 trial)

melatonin (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

Drugs in Phase 2 Trials (2)

ketamine (ketalar) (1 trial)

metformin (glucophage) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Treatment-Resistant (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Shock (Phase 3)

Shock, Septic (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 7